Repligen Co. (NASDAQ:RGEN) Shares Acquired by UMB Bank n.a.

UMB Bank n.a. grew its position in shares of Repligen Co. (NASDAQ:RGEN) by 99.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 666 shares of the biotechnology company’s stock after purchasing an additional 332 shares during the quarter. UMB Bank n.a.’s holdings in Repligen were worth $85,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Signaturefd LLC increased its holdings in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new stake in shares of Repligen during the 4th quarter valued at about $29,000. Raiffeisen Bank International AG purchased a new position in shares of Repligen in the 4th quarter valued at about $29,000. Itau Unibanco Holding S.A. purchased a new position in shares of Repligen in the 4th quarter valued at about $40,000. Finally, Global Retirement Partners LLC raised its holdings in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 129 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. JPMorgan Chase & Co. dropped their price target on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Wall Street Zen upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Thursday, May 8th. Wolfe Research raised shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. Finally, Canaccord Genuity Group cut their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.25.

Repligen Stock Performance

NASDAQ:RGEN opened at $131.30 on Friday. The company’s 50-day moving average price is $128.21 and its 200-day moving average price is $143.09. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.38 billion, a P/E ratio of -257.45, a P/E/G ratio of 4.54 and a beta of 1.11. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.28 EPS. On average, sell-side analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.